Table 2.
Univariate and multivariate cox analysis of RFS in the training cohort (n = 195).
| Factor | RFS | |||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | |||||
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
| Sex (female vs. male) | 1.467 | 0.874–2.462 | 0.147 | NA | ||
| Age, years (≤50 vs. >50) | 1.165 | 0.792–1.713 | 0.437 | NA | ||
| HBsAg (negative vs. positive) | 1.167 | 0.686–1.983 | 0.569 | NA | ||
| AFP, ng/ml (≤20 vs. >20) | 1.248 | 0.844–1.845 | 0.267 | NA | ||
| GGT, U/l (≤54 vs. >54) | 1.832 | 1.255–2.676 | 0.002 | 1.652 | 1.117–2.441 | 0.012 |
| Liver cirrhosis (no vs. yes) | 1.739 | 1.023–2.956 | 0.041 | 1.989 | 1.156–3.423 | 0.013 |
| Tumour size, cm (≤5 vs. >5) | 1.592 | 1.086–2.333 | 0.017 | 1.420 | 0.935–2.154 | 0.100 |
| Microvascular invasion (no vs. yes) | 1.640 | 1.110–2.423 | 0.013 | 1.523 | 0.707–3.277 | 0.282 |
| Tumour differentiation (I–II vs. III–IV) | 1.661 | 1.104–2.499 | 0.015 | 1.509 | 0.996–2.287 | 0.052 |
| TNM stage (I vs. II) | 1.713 | 1.133–2.590 | 0.011 | 1.107 | 0.492–2.490 | 0.805 |
| BCLC stage (0 vs. A) | 1.083 | 0.645–1.818 | 0.762 | NA | ||
| HCC-IHC classifier (high vs. low) | 1.649 | 1.133–2.400 | 0.009 | 1.593 | 1.083–2.344 | 0.018 |
Cox proportional hazards regression.
RFS relapse-free survival, AFP α-fetoprotein, ALT alanine aminotransferase, GGT γ-glutamyl transpeptidase, TNM tumour–nodes–metastasis, BCLC Barcelona Clinic Liver Cancer, HR hazard ratio, CI confidential interval, NA not adopted.